Li John Wing, Wong Joseph Ho Sing, Chak Wai Leung, Chau Ka Foon
Renal Unit, Queen Elizabeth Hospital, Hong Kong, China.
Hemodial Int. 2018 Jul;22(3):308-317. doi: 10.1111/hdi.12616. Epub 2017 Oct 18.
While studies demonstrated favorable outcomes of nocturnal home hemodialysis (NHHD), direct comparison on employment rate, clinical and laboratory outcomes between the NHHD and continuous ambulatory peritoneal dialysis (CAPD) had not been previously performed.
A 1-year retrospective observation study was performed in 20 incidents alternate night NHHD and 81 incident CAPD patients of Chinese ethnicity, who were sex, diabetic status, and Charlson comorbidity index matched, but not age due to our center's age limit for NHHD enrollment. The primary outcome was the difference in employment rate at 1 year. Secondary outcomes included differences in clinical parameters (weight, blood pressure, number of antihypertensive medication, dosage of phosphate binders, and erythropoietin stimulating agent) and laboratory parameters (residual renal function, mineral metabolic markers, hemoglobin).
NHHD subjects were 5 years younger than CAPD patients, and they had higher employment rate (80% vs. 33.3%, P < 0.01) at 1 year, with age-adjusted odds ratio for employment was 6.10 (95% confidence interval 1.77-20.99, P = 0.04). They consumed less aluminum-based phosphate binder (0 vs. 1800 mg, P < 0.01), but showed no significant disparities in other clinical parameters. Residual renal function in both groups declined comparably, nonetheless NHHD group had lower serum phosphate (1.37 vs. 1.71 mmol/L, P = 0.01) and calcium phosphate product (3.13 vs. 4.12 mmol /L , P < 0.01), with similar hemoglobin levels.
NHHD appeared to offer higher employment rate, lower dosage of aluminum-based phosphate binder and mineral metabolic markers at 1 year compared with CAPD in Hong Kong.
虽然研究表明夜间家庭血液透析(NHHD)有良好的效果,但此前尚未对NHHD与持续性非卧床腹膜透析(CAPD)的就业率、临床和实验室结果进行直接比较。
对20例接受隔日夜间NHHD治疗的患者和81例初发CAPD患者进行了为期1年的回顾性观察研究,这些患者均为中国汉族,在性别、糖尿病状态和Charlson合并症指数方面进行了匹配,但由于本中心NHHD入组的年龄限制,未对年龄进行匹配。主要结局是1年时的就业率差异。次要结局包括临床参数(体重、血压、抗高血压药物数量、磷结合剂剂量和促红细胞生成素刺激剂)和实验室参数(残余肾功能、矿物质代谢标志物、血红蛋白)的差异。
NHHD组患者比CAPD组患者年轻5岁,1年时的就业率更高(80%对33.3%,P<0.01),年龄调整后的就业优势比为6.10(95%置信区间1.77 - 20.99,P = 0.04)。他们消耗的铝基磷结合剂较少(0对1800毫克,P<0.01),但在其他临床参数方面没有显著差异。两组的残余肾功能下降程度相当,尽管如此,NHHD组的血清磷水平较低(1.37对1.71毫摩尔/升,P = 0.01),钙磷乘积较低(3.13对4.12毫摩尔/升,P<0.01),血红蛋白水平相似。
在香港,与CAPD相比,NHHD在1年时似乎能提供更高的就业率、更低的铝基磷结合剂剂量和矿物质代谢标志物水平。